title: Treating malignant glioma in Chinese patients: update on temozolomide.
abstract: Malignant glioma, ie, anaplastic astrocytoma and glioblastoma, is the most common type of primary malignant brain tumor in the People's Republic of China, and is particularly aggressive. The median survival of patients with newly diagnosed glioblastoma is only 12-14 months despite advanced therapeutic strategies. Treatment of malignant glioma consists mainly of surgical resection followed by adjuvant radiation and chemotherapy. Temozolomide (TMZ), a second-generation oral alkylating agent, is playing an increasingly important role in the treatment of malignant glioma in Chinese patients. Since the publication of a study by Stupp et al in 2005, which used a protocol of conventional fractionated irradiation with concomitant TMZ followed by standard TMZ for six cycles, many clinical studies in the People's Republic of China have demonstrated that such a treatment strategy has significantly improved efficacy with limited side effects for newly diagnosed glioblastoma after surgery as compared with strategies that do not contain TMZ. However, as a relatively new agent, the history and development of TMZ for malignant glioma is not well documented in Chinese patients. Multicenter, randomized controlled trials including appropriately sized patient populations investigating multiple aspects of TMZ therapy and related combination therapies are warranted in patients with malignant glioma. This review provides an update on the efficacy, mechanism of action, adverse reactions, and clinical role of TMZ in the treatment of malignant glioma in Chinese patients.
authors.affiliation: Department of Neurosurgery, The Tumor Hospital of Harbin Medical University, People's Republic of China.
authors.forename: Liang
authors.initials: L
authors.lastname: Chang
authors.affiliation: Department of Neurosurgery, The Tumor Hospital of Harbin Medical University, People's Republic of China.
authors.forename: Jun
authors.initials: J
authors.lastname: Su
authors.affiliation: Department of Immunology, Harbin Medical University, People's Republic of China ; Key Lab Infection and Immunity, Heilongjiang Province, Harbin, People's Republic of China.
authors.forename: Xiuzhi
authors.initials: X
authors.lastname: Jia
authors.affiliation: Department of Immunology, Harbin Medical University, People's Republic of China ; Key Lab Infection and Immunity, Heilongjiang Province, Harbin, People's Republic of China.
authors.forename: Huan
authors.initials: H
authors.lastname: Ren
keywords: People’s Republic of China; chemotherapy; efficacy; malignant glioma; side effect; temozolomide